Enzymatic activity of paraoxonase depending on polymorphism Q192R of the PON1 gene in patients with primary open-angle glaucoma

Close metadata

PURPOSE

To genotype patients with primary open-angle glaucoma (POAG) by the Q192R polymorphism of the PON1 gene in order to identify their genetic predisposition to dyslipidemia and atherosclerosis, as well as to determe the possibility of correcting the reduced activity of the PON1 enzyme in the examined individuals by the complex drug Cytoflavin.

MATERIAL AND METHODS

The study included 25 men with advanced POAG, IOP compensated by hypotonic agents, and 20 volunteers without POAG (mean age 63.0±5.4 years). All subjects underwent genotyping by the Q192R polymorphism of the PON1 gene using an analyzer. PON1 activity was assessed by the rate of nitrophenol formation when paraoxone diluted in acetone was added to the blood plasma. At the second stage, patients (of different phenotypes) were prescribed the complex drug Cytoflavin.

RESULTS

Homozygous carriers of the 192R allele were found to have significantly lower levels of PON1 activity than homozygous carriers of the Q192 allele. Carriage of the 192R allele may determine an increased risk of atherosclerotic injury in patients with POAG, especially in cases with high levels of atherogenic blood lipoproteins, low levels of high-density lipoproteins, or high levels of peroxidized lipids in the blood. The drug Cytoflavin showed a positive therapeutic effect on oxidative stress and hypercholesterinemia in POAG patients.

CONCLUSION

These findings can be used to determine the atherogenicity of lipoproteins and the progression of glaucomatous optic neuropathy and to optimize the therapy of PAHO.

Keywords:

primary open-angle glaucoma

PON1 gene

paraoxonase enzyme 1

lipid metabolism

atherosclerosis

Cytoflavin

Authors:

Filippova Yu.E.

Regional Ophthalmological Dispensary

ORCID: 0000-0001-5035-3128

Malishevskaya T.N.

Helmholtz National Medical Research Center of Eye Diseases

ORCID: 0000-0003-3679-8619

Petrov S.A.

Tyumen Scientific Centre SB RAS

SPIN RSCI: 8382-8583
ORCID: 0000-0002-1566-2299

Gubin D.G.

Tyumen State Medical University;
Tyumen Cardiological Research Center — branch of the Tomsk National Research Medical Center of the Russian Academy of Sciences

Vlasova A.S.

Tyumen Regional Ophthalmological Dispensary;
West-Siberian Institute of Postgraduate Medical Education

Received:

14.02.2022

Accepted:

14.03.2022

List of references:

Skrzypecki J, Ufnal M, Szaflik J, Filipiak K. Blood pressure and glaucoma: At the crossroads between cardiology and ophthalmology. Cardiol J. 2019; 26(1):8-12. https://doi.org/10.5603/CJ.2019.0008
Tabak S, Schreiber-Avissar S, Beit-Yannai E. Crosstalk between MicroRNA and Oxidative Stress in Primary Open-Angle Glaucoma. Int J Mol Sci. 2021; 22:2421. https://doi.org/10.3390/ijms22052421
Lerner N, Chen I, Schreiber-Avissar S, Beit-Yannai E. Extracellular Vesicles Mediate Anti-Oxidative Response — In Vitro Study in the Ocular Drainage System. Int J Mol Sci. 2020;21:6105. https://doi.org/doi:10.3390/ijms21176105
Malishevskaya TN, Kiseleva TN, Filippova YuE, Zaitsev MS, Vlasova AS, Nemtsova IV, Lugovkina KV. State of antioxidant status and lipid spectrum of blood in patients with different variants of the course of primary open-angle glaucoma. Ophthalmology = Oftalmologiya. 2020;17(4):761-770. (In Russ.) https://doi.org/10.18008/1816-5095-2020-4- 761-770
Jung Y, Han K, Park HYL, Lee SH, Park CK. Metabolic Health, Obesity, and the Risk of Developing Open-Angle Glaucoma: Metabolically Healthy Obese Patients versus Metabolically Unhealthy but Normal Weight Patients. Diabetes Metab J. 2020;44:414-425. https://doi.org/10.4093/dmj.2019.0048
Kim HA, Han K, Lee YA, Choi JA, Park YM. Differential association of metabolic risk factors with open angle glaucoma according to obesity in a Korean population. Sci Rep. 2016;6:38283. https://doi.org/10.1038/srep38283
Kim M, Jeoung JW, Park KH, Oh WH, Choi HJ, Kim DM. Metabolic syndrome as a risk factor in normal-tension glaucoma. Acta Ophthalmol. 2014; 92:637-643. https://doi.org/10.1111/aos.12434
Flammer J, Mozaffarieh M. Autoregulation, a balancing act between supply and demand. Can J Ophthalmol. 2008;43:317-321. https://doi.org/10.1139/I08-056
Song X, Li P, Li Y, Yan X, Zhao C, An Y, Chang X. Strong association of glaucoma with atherosclerosis. Sci Rep. 2021;11:8792. https://doi.org/10.1038/s41598-021-88322-4
Iughetti L, Volta C, Maggi E, et al. Circulating antibodies recognizing oxidatively modified lowdensity lipoprotein in children. Pediatr Res. 1999; 45(1):94-99.
Coombes RH, Crow JA, Dail MB, et al. Relationship of human paraoxonase-1 serum activity and genotype with atherosclerosis in individuals from the Deep South. Pharmacogenet Genomics. 2011;21(12):867-875. https://doi.org/10.1097/fpc.0b013e32834cebc6
Mackness MI, Arrol S, Abbot C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
Levy BD, Kohli P, Gotlinger K, et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol. 2007;178(1):496-502. https://doi.org/10.4049/jimmunol.178.1.496
Bacchetti T, Campanati A, Ferretti G, Simonetti O, Liberati G, Offidani AM. Oxidative stress and psoriasis: the effect of antitumour necrosis factor‐α inhibitor treatment. Br J Dermatol. 2013;168(5):984-989. https://doi.org/10.1111/bjd.12144
Farid AS, Horii Y. Modulation of paraoxonases during infectious diseases and its potential impact on atherosclerosis. Lipids Health Dis. 2012;11:92.
Lucero D, Islam P, Freeman LA, et al. Interleukin 10 promotes macrophage uptake of HDL and LDL by stimulating fluid‐phase endocytosis. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865(2):158537. https://doi.org/10.1186/1476-511X-11-92
Gordon EM, Yao X, Xu H, et al. Apolipoprotein E is a concentration‐dependent pulmonary danger signal that activates the NLRP3 in flammasome and IL-1β secretion by bronchoalveolar fluid macrophages from asthmatic subjects. J Allergy Clin Immunol. 2019;144(2):426-441.e423.
Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008; 299:1265-1276. https://doi.org/10.1001/jama.299.11.1265
Efimtseva EA, Chelpanova TI. Paraoxonase: molecular genetic aspects and clinical significance. Biology Bulletin Reviews = Uspekhi sovremennoy biologii. 2012;132(3):282-296. (In Russ.).
Yilmaz N, Coban DT, Bayindir A, Erol MK, Ellidag HY, Giray O, Sayrac S, Tekeli SO, Eren E. Higher serum lipids and oxidative stress in patients with normal tension glaucoma, but not pseudoexfoliative glaucoma. Bosn J Basic Med Sci. 2016;16(1):21-27. https://doi.org/10.17305/bjbms.2016.830
Zhang B, Eto S, Fan P, et al. Paraoxonase (Pon1) Q192R polymorphism and serum PON1 activity in diabetic patients on maintenance hemodialysis. Clin Nephrol. 2003;60(4):257-265.
Costa L, Giordano G, Furlong C. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol. 2011;81(3):337-344. https://doi.org/10.1016/j.bcp.2010.11.008
Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier C, et all. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999; 26(7-8):892-904. https://doi.org/10.1016/s0891-5849(98)00272-x.
Stel’makh VV, Nekrasova AS, Kozlov VK. Efficacy of combined therapy of non-alcoholic fatty liver disease with succinate-containing drugs. Klinicheskaya meditsina. 2016;94(11):836-842. (In Russ.).
Malishevskaya TN, Yusupov AZ, Shatsky SV, Antipina NA, Klindyuk TS, Bogdanova DS. Study of the effectiveness and safety of neuroprotection in primary open-angle glaucoma. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2019;(2):77-85. (In Russ.).
Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473.
Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19(2):330-335. https://doi.org/10.1161/01.ATV.19.2.330
Gorshunskaya MYu, Karachentsev MYu, Atramentova LA, et al. Polymorphism of the Q192R PON1 gene in patients with type 2 diabetes mellitus. Cytology and Genetics = Tsitologiya i genetika. 2011;(1):48-51. (In Russ.).
Pchelina SN, Yemel’yanov AK, Usenko TS. Molecular bases of Parkinson’s disease due to mutations in the LRRK2 gene. Molecular Biology = Molekulyarnaya biologiya. 2014;48(1):3-14. (In Russ.).

Close metadata